{"id":59689,"date":"2023-04-28T06:46:58","date_gmt":"2023-04-28T06:46:58","guid":{"rendered":"https:\/\/dailytalks.org\/?p=59689"},"modified":"2023-04-28T06:46:58","modified_gmt":"2023-04-28T06:46:58","slug":"immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=59689","title":{"rendered":"ImmunoPrecise\u2019s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas"},"content":{"rendered":"<p>Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will Leverage BioStrand\u2019s (a Talem Affiliate) LENSai\u00ae Integrated Intelligence Technology\u00ae, Built Upon the Proprietary HYFT Index\u00ae. VICTORIA, British Columbia \u2014 ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (\u201cImmunoPrecise\u201d or \u201cIPA\u201d or the \u201cCompany\u201d) an AI-driven biotherapeutic research and technology [\u2026&#8230;<br \/><a href=\"https:\/\/financialpost.com\/pmn\/press-releases-pmn\/business-wire-news-releases-pmn\/immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor<\/p>\n","protected":false},"author":1,"featured_media":59690,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":["post-59689","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas.jpg",1000,750,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas-300x225.jpg",300,225,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas-768x576.jpg",640,480,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas.jpg",640,480,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas.jpg",1000,750,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas.jpg",1000,750,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas.jpg",1000,750,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/04\/59689-immunoprecises-subsidiary-talem-enters-into-exclusive-research-collaboration-and-license-option-agreement-with-astellas-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=35\" rel=\"category\">Tech<\/a>","tag_info":"Tech","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/59689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59689"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/59689\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/59690"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}